CTK Biotech, Inc. and the United States Centers for Disease Control and Prevention (CDC) have reached a license agreement that grants CTK the worldwide-exclusive, diagnostic commercial rights to a patented dengue virus developed by a CDC laboratory. Utilizing this advanced technology, CTK has recently launched an improved line of its OnSite Rapid Tests for the detection of anti-dengue IgG and IgM in serum, plasma and whole blood specimens.
Early identification and distinguishing between primary and secondary infections can lead to early treatment aimed to limit the severity of the disease, an important step in reducing mortality rates. Our top priority at CTK is to develop high quality, cutting-edge point of care diagnostic products that effectively respond to the needs of the population. Our recent partnership with the CDC positions us at the forefront of the IVD market with the advantage of using the most advanced dengue technology for our research and development.